• Home
  • Contributors
  • Glossary
  • Subscribe

Bioasis Technologies Inc.

The Science of Melanotransferrin (p97)

From the category archives:

mental illness

Controversy-plagued Genzyme Refuses Sanofi Acquisition

by Mahesh on September 7, 2010

Will Anti-Amyloid Failures Change Pharma Approach?

by Mahesh on August 26, 2010

Eli Lilly Challenged By Its Neuroscience Pipeline

by Mahesh on August 25, 2010

Parkinson’s and Alzheimer’s May Share Treatment Potential

by Mahesh on August 17, 2010

Biomarker Tests Can Revolutionize Alzheimer’s Diagnosis and Treatment

by Mahesh on August 10, 2010

Venture Capital Financing Warms Slowly in 2010

by Mahesh on August 5, 2010

New Aricept Doses Approved by FDA

by Mahesh on July 30, 2010

MIT Study Links Mouse Model to Genetics of Alzheimer’s

by Mahesh on July 27, 2010

Anti-amyloid Bapineuzumab may affect Tau levels in CSF

by Mahesh on July 22, 2010

Pfizer and Eli Lilly Support Avid’s Biomarker Success

by Mahesh on July 20, 2010

← Previous Entries

  • Pages

    • Contributors
    • Glossary
    • Robin (Rob) B. Hutchison, Chairman & CEO
  • Recent Posts

    • Sleep Disorder Predicts Dementia?
    • Controversy-plagued Genzyme Refuses Sanofi Acquisition
    • Mental Exercises Affect Alzheimer’s Disease
    • Blood-Brain Barrier Carriers – the Next Frontier for CNS Diseases?
    • What If Amyloid Actually Protected The Brain?
  • Categories

    • ADDL (1)
    • age-related neurodegenerative disease (150)
    • Alzheimer's Research (194)
    • amyloid beta deposits/plaques (64)
    • amyloid protein vaccination (4)
    • antidepressants (4)
    • axon deterioration (53)
    • BioAsis (106)
    • biosecurity (1)
    • biosimilar therapies (23)
    • biotechnology (151)
    • bioterrorism (1)
    • Blood Brain Barrier (53)
    • CEO (2)
    • cholinergic effects (1)
    • chronic neurological diseases (81)
    • Citizen Petition (4)
    • dementia (71)
    • diabetes (5)
    • DNA (5)
    • Dr. Wilf Jefferies (3)
    • FDA (14)
    • Frontotemporal Dementia (19)
    • Genentech (9)
    • Health reform (17)
    • Huntington's Disease (11)
    • Huntington’s Disease (5)
    • immunotherapy (1)
    • LDT (1)
    • Lewy Body Variant (5)
    • Melanotransferrin (64)
    • mental illness (51)
    • MOCA (2)
    • Neurological Diseases (163)
    • neurological disorders (68)
    • New Studies (18)
    • Not-for-Profit Organisations (9)
    • P97 (81)
    • Parkinson's (22)
    • Parkinson's Disease (32)
    • Parkinson’s (8)
    • personalized medicine (7)
    • Pfizer (36)
    • Pharma (31)
    • prescription medicine (13)
    • research cutbacks (31)
    • Research tools (4)
    • SEB (2)
    • Subsequent Entry Biologics (2)
    • tau tangles (30)
    • team members (3)
    • Uncategorized (29)
    • Unconventional treatments (4)
    • Vascular Dementia (23)
    • Wyeth (21)
  • Recent Comments

    • Blood-Brain Barrier Carriers - the Next Frontier for CNS Diseases? on The Blood-Brain Barrier: A Major Hurdle For Neurological Drug Delivery
    • What If Amyloid Actually Protected the Brain? on Will Anti-Amyloid Failures Change Pharma Approach?
    • Will Anti-Amyloid Failures Failures Change Pharma Approach? on Bapineuzumab’s Phase II Results Published – AD Drug Fails Expectations
    • Willa Zavala on Be Careful of Some Home Remedies for Alzheimer’s Disease
    • Biomarker Tests Can Revolutionize Alzheimer's Diagnosis and Treatment on biOasis CEO Rob Hutchison provides shareholder update
  • Archives

    • September 2010 (5)
    • August 2010 (17)
    • July 2010 (19)
    • June 2010 (18)
    • May 2010 (16)
    • April 2010 (17)
    • March 2010 (17)
    • February 2010 (15)
    • January 2010 (15)
    • December 2009 (16)
    • November 2009 (16)
    • October 2009 (17)
    • September 2009 (18)
    • August 2009 (18)
    • July 2009 (18)
    • June 2009 (15)
    • May 2009 (13)
    • April 2009 (13)
    • March 2009 (10)
    • February 2009 (16)
    • January 2009 (4)
    • September 2008 (1)
  • Categories

    • ADDL
    • age-related neurodegenerative disease
    • Alzheimer's Research
    • amyloid beta deposits/plaques
    • amyloid protein vaccination
    • antidepressants
    • axon deterioration
    • BioAsis
    • biosecurity
    • biosimilar therapies
    • biotechnology
    • bioterrorism
    • Blood Brain Barrier
    • CEO
    • cholinergic effects
    • chronic neurological diseases
    • Citizen Petition
    • dementia
    • diabetes
    • DNA
    • Dr. Wilf Jefferies
    • FDA
    • Frontotemporal Dementia
    • Genentech
    • Health reform
    • Huntington's Disease
    • Huntington’s Disease
    • immunotherapy
    • LDT
    • Lewy Body Variant
    • Melanotransferrin
    • mental illness
    • MOCA
    • Neurological Diseases
    • neurological disorders
    • New Studies
    • Not-for-Profit Organisations
    • P97
    • Parkinson's
    • Parkinson's Disease
    • Parkinson’s
    • personalized medicine
    • Pfizer
    • Pharma
    • prescription medicine
    • research cutbacks
    • Research tools
    • SEB
    • Subsequent Entry Biologics
    • tau tangles
    • team members
    • Uncategorized
    • Unconventional treatments
    • Vascular Dementia
    • Wyeth

Get smart with the Thesis WordPress Theme from DIYthemes.

WordPress Admin